Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

George Yancopoulos, co-founder of biotech firm Regeneron, has purchased almost all of the condominium units in a mixed-use ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

We applaud Regeneron's moat-building investment strategies and good allocation of capital. On investments, Regeneron's focus has largely been on developing its internal pipeline of oncology and ...

Regeneron does not undertake any obligation ... With physician and patient awareness building and strong reimbursement established, the COPD launch has outperformed all other Dupixent indication ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron is also expanding its Tarrytown, New York-based facility and building a separate facility in the state to expand capacity to fill injection pens - a process known as fill-finish.

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...